Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive genetic disorder (ORPHA:444490) of chylomicron metabolism 1 that results in severe hypertriglyceridemia (sHTG) and recurrent episodes of acute pancreatitis attacks 2, due to very low or even absent lipoprotein lipase (LPL) activity 3. FCS-related genes are the LPL gene per se, and those affecting the correct folding and migration/location of LPL, such as the lipase maturation factor 1 (LMF1) and glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1), respectively. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - January 25, 2023 Category: Lipidology Authors: Jos é Rioja, María José Ariza, María José Benítez-Toledo, Javier Espíldora-Hernández, Inmaculada Coca-Prieto, Teresa Arrobas-Velilla, Ana Camacho, Gunilla Olivecrona, Miguel Ángel Sánchez-Chaparro, Pedro Valdivielso Source Type: research
The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia
Familial Hypercholesterolaemia (FH) is a common monogenic disorder of low-density-lipoprotein cholesterol (LDL-C) associated with premature cardiovascular disease (CVD).1 Untreated, the cumulative incidence of ischaemic heart disease in men and women is 50% by age 50, and 60% by age 60, respectively.2 The 2013 consensus panel statement from the European Atherosclerosis Society highlights that FH is underdiagnosed and undertreated, and a ‘call to arms’ was recently issued to address screening, diagnosis, and treatment, supported by development of a global FH registry: the European Atherosclerosis Society FH Studies Coll...
Source: Journal of Clinical Lipidology - January 25, 2023 Category: Lipidology Authors: Darmiga Thayabaran, Anson .P.T. Tsui, Stefan Ebmeier, Jaimini Cegla, Alessia David, Ben Jones Source Type: research
JCL Roundtable: Lipidology and Women's Health
In this JCL Roundtable, we bring together three experts to discuss women's cardiovascular health throughout the lifespan, viewed from the standpoint of clinical lipidology. Overall, heart disease leads to one out of every 3 deaths of American women, but unfortunately patient awareness of cardiovascular risk actually has declined since 2009. Younger women are not exempt, since their risk can be increased by smoking, birth control, adverse lifestyle and diet, and genetic disorders. Age at menarche can influence lifetime risk. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - January 1, 2023 Category: Lipidology Authors: Eugenia Gianos, Emily S. Lau, Samar R. El Khoudary, John R. Guyton Source Type: research
From the editor: Intensive exercise and insights from women
Soon I expect to see in clinic a woman in her mid-50s who exercises intensively, has only moderate hypercholesterolemia, and yet already has a positive coronary artery calcium (CAC) score near the 80th percentile for her age. Could her level of exercise actually have contributed to the high CAC score? Last year in my lipid clinic, 3 or maybe 4 patients described similar intensive exercise, usually over decades of life, and unexpectedly high CAC. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - January 1, 2023 Category: Lipidology Authors: John R. Guyton Source Type: research
News from NLA
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - January 1, 2023 Category: Lipidology Source Type: research
Editorial Board
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - January 1, 2023 Category: Lipidology Source Type: research
Table of Contents
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - January 1, 2023 Category: Lipidology Source Type: research
Recommended and Observed Statin Use among U.S. Adults – National Health and Nutrition Examination Survey, 2011-2018
Heart disease and stroke are the first and fifth leading causes of death in the United States.1 A leading risk factor for both conditions, high blood cholesterol levels are positively associated with atherosclerotic cardiovascular disease (ASCVD).2-5 The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013 Cholesterol Guideline) eliminated specific LDL-c treatment targets, shifted treatment focus to use of HMG-CoA reductase inhibitors (statins), identified four patient groups most likely to bene...
Source: Journal of Clinical Lipidology - December 24, 2022 Category: Lipidology Authors: Angela M. Thompson-Paul, Cathleen Gillespie, Hilary K. Wall, Fleetwood Loustalot, Laurence Sperling, Yuling Hong Tags: Original Research Source Type: research
Adherence to Statin Treatment in Patients with Familial Hypercholesterolemia: a Dynamic Prediction Model
Familial hypercholesterolemia (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 23, 2022 Category: Lipidology Authors: Arjen J. Cupido, Michel H. Hof, Lotte M. de Boer, Roeland Huijgen, Erik S.G. Stroes, John J.P. Kastelein, G. Kees Hovingh, Barbara A. Hutten Tags: Original Research Source Type: research
Counseling Couples at Risk of Having a Child with Homozygous Familial Hypercholesterolemia – Clinical Experience and Recommendations
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder with a prevalence of approximately 1 in 3001, characterized by elevated low-density lipoprotein cholesterol (LDL-C) causing accelerated atherosclerosis and increased risk of premature cardiovascular disease (CVD). Early detection and initiation of lipid-lowering therapy (LLT) are crucial to negate this elevated risk.2,3 HeFH is caused by a pathogenic variant in genes encoding proteins involved in cholesterol metabolism (LDLR, APOB or PCSK9). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 23, 2022 Category: Lipidology Authors: Tycho R. Tromp, M. Doortje Reijman, Albert Wiegman, G. Kees Hovingh, Joep C. Defesche, Merel C. van Maarle, Inge B. Mathijssen Tags: Brief Communication Source Type: research
Impact of telehealth on the current and future practice of lipidology: a scoping review
Clinicians have used telehealth services for decades and evidence shows that it reduces hospital readmissions, increases savings for both patients and providers, and enhances quality of patient care.1 According to the World Health Organization, telemedicine is defined as the use of information and communication technologies to improve patient outcomes by increasing access to care and medical information.2 The American Telemedicine Association considers telemedicine to be synonymous with telehealth. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 16, 2022 Category: Lipidology Authors: Tyler J. Schubert, Katarina Clegg, Dean Karalis, Nihar R. Desai, Joel C. Marrs, Catherine McNeal, Guy L. Mintz, Katrina M. Romagnoli, Laney K. Jones Tags: Review Article Source Type: research
Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience
Low-density lipoprotein cholesterol (LDL-C) is a well-established and important cardiovascular risk factor. HMG-CoA reductase inhibitor (statin) therapy is the first line of lipid-lowering treatment for atherosclerotic cardiovascular disease (ASCVD) risk reduction.1-3 In the IMPROVE-IT trial, the addition of ezetimibe to statin therapy has also demonstrated a significant, if modest, additional clinical benefit on ASCVD risk reduction.4 However, residual CV risk remains a major concern. Indeed, according to results from the HELLAS-FH registry, LDL-C target attainment using the 2019 ESC/EAS guidelines was 2.7%. (Source: Jour...
Source: Journal of Clinical Lipidology - December 7, 2022 Category: Lipidology Authors: Martine Paquette, Simon Faubert, Nathalie Saint-Pierre, Alexis Baass, Sophie Bernard Tags: Original Research Source Type: research
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
Lipoprotein(a) [Lp(a)] is a unique lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B-100 of an LDL-like particle.1,2 The strong and consistent genetic and epidemiological evidence of elevated Lp(a) as an independent risk factor for cardiovascular disease and aortic stenosis has generated intense interest in developing novel therapies to lower plasma levels.3 Due to the fact that Lp(a) levels are primarily determined by the synthetic rate of apolipoprotein(a) in hepatocytes, liver-targeted therapies are ideally suited to treat elevated Lp(a). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 7, 2022 Category: Lipidology Authors: Ewa Karwatowska ‑Prokopczuk, Anastasia Lesogor, Jing-He Yan, Eunju Hurh, Angelika Hoenlinger, Alison Margolskee, Shuting Xia, Sotirios Tsimikas Tags: Original Research Source Type: research
Impact of the eicosapentaenoic acid to arachidonic acid ratio on plaque characteristics in statin-treated patients with coronary artery disease
A low eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is an indicator of increased risk for cardiovascular events 1,2. Preclinical and clinical studies have demonstrated that EPA stabilizes plaques by inducing an anti-inflammatory response and reducing platelet aggregation 3,4,5. In contrast, AA facilitates plaque instability through the activation of inflammatory processes and platelet activation 6,7. Thus, having a low EPA/AA ratio may destabilize and progress the coronary plaques and cause subsequent adverse coronary event 8,9. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 2, 2022 Category: Lipidology Authors: Kiyoshi Asakura, Yoshiyasu Minami, Takako Nagata, Masahiro Katamine, Aritomo Katsura, Takuya Hashimoto, Daisuke Kinoshita, Junya Ako Tags: Original Research Source Type: research
Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Statin therapy is widely prescribed for patients with established ASCVD (secondary prevention). Meta-analysis of randomized clinical trials (RCTs) show conclusively that statins substantially reduce recurrent major ASCVD events (myocardial infarction and stroke)1. More problematic is use of statins for patients without ASCVD (primary prevention). RCTs clearly demonstrate that statins can lower ASCVD for primary prevention in patients at higher risk for future vascular events2-4; however, the number needed to treat (NNT) to prevent one ASCVD event is much higher for primary prevention than for secondary prevention. (Source:...
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Scott M. Grundy, Jijia Wong, Gloria L. Vega Source Type: research
